Skip to main content

Page of 2 next disabled
and
  1. Article

    Open Access

    Two types of amyloidosis presenting in a single patient: a case series

    The amyloidoses are a group of disorders with overlap** clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein de...

    M. Hasib Sidiqi, Ellen D. McPhail, Jason D. Theis, Surendra Dasari in Blood Cancer Journal (2019)

  2. Article

    Open Access

    Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

    Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand intera...

    Shahrzad Jalali, Tammy Price-Troska, Cole Bothun, Jose Villasboas in Blood Cancer Journal (2019)

  3. Article

    Open Access

    Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma

    MYD88 mutations are one of the most recurrent mutations in hematologic malignancies. However, recent mouse models suggest that MYD88L265P alone may not be sufficient to induce tumor formation. Interplay between M...

    Kerstin Wenzl, Michelle K. Manske, Vivekananda Sarangi in Blood Cancer Journal (2018)

  4. Article

    Open Access

    Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies

    Advances in therapy in recent years have led investigators to challenge the dogma that multiple myeloma (MM) is incurable. We assessed overall (OS) and progression-free survival (PFS) of young patients ( ≤ 50 ...

    Praful Ravi, Shaji K. Kumar, James R. Cerhan, Matthew J. Maurer in Blood Cancer Journal (2018)

Page of 2 next disabled